



**Proteomics International**

LABORATORIES LTD

**ASX Release**

**8 April 2025**

**ASX code: PIQ**

## **Investor Presentation Morgan Stanley Alpha ex-100 Conference**

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce its Managing Director Dr Richard Lipscombe and Chief Commercial Officer Mr Phillip Prather will give the attached investor briefing at the Alpha ex-100 Conference hosted by Morgan Stanley in Sydney today.

Authorised by the Chair and the Managing Director on behalf of the Board of PIQ.

ENDS

### **About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

### **For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Dirk van Dissel  
Investor Relations  
Candour Advisory  
T: +61 408 326 367  
E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

**Proteomics International Laboratories Ltd**

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)



ASX: PIQ

# Proteomics International

LABORATORIES LTD

## Morgan Stanley Alpha ex-100 Conference

Investor Presentation

8 April 2025

Dr Richard Lipscombe  
Managing Director

Philip Prather  
Chief Commercial Officer

This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ).

You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase the shares of the Company. This is not an offer to subscribe for securities in the Company.

The Presentation may contain quantitative statements of anticipated future performance such as projections, forecasts, calculations, forward-looking statements or estimates all of which are based on certain assumptions (Forward Looking Statements). The Forward Looking Statements may involve subjective judgements and are based on a large number of assumptions and are subject to significant uncertainties and contingencies, many of which are outside the control of the Company and may not prove to be correct.

No representation or warranty is made that any Forward Looking Statements will be achieved, or occur, or that the assumptions upon which they are based are reasonable or the calculations from which they have been derived are correct. Actual future events may vary significantly from the Forward Looking Statements. Each Recipient should undertake their own independent review of the Forward Looking Statements, including the assumptions on which they are based and the financial calculations from which they are derived.

A medical technology company at the forefront of precision diagnostics

Launching four first-in-class tests driven by a proprietary platform technology:

## Promarker<sub>D</sub>

Diabetic Kidney Disease

COMMERCIALISATION

- A novel and accurate blood test for predicting the onset of chronic kidney disease in type 2 and type 1 diabetes (DKD)
- 10.5% of adults worldwide currently have diabetes with **32 million in the US alone – currently 1 in 2 will develop DKD**
- US reimbursement price set at USD \$391

## Promarker<sub>Endo</sub>

Endometriosis

DEVELOPMENT COMMERCIALISATION

- First-in-class blood test identifies all stages of endometriosis with high accuracy (sensitivity and specificity up to 96%)
- **Affects 1 in 9 women worldwide**; costs Australia alone over AUD \$10bn p.a.
- Current average 7 years for diagnosis: **replaces diagnostic laparoscopy**

## Promarker<sub>Eso</sub>

Esophageal Cancer

DEVELOPMENT COMMERCIALISATION

- A novel blood test to diagnose esophageal cancer - clinical validation study identified 94% of patients with the disease
- **Caused by chronic acid reflux** (or 'GERD'), 1 in 20 cancer deaths worldwide are due to esophageal cancer
- **Replaces endoscopy/biopsy: 1.5 million per year in US**

## OxiDx

Oxidative Stress

DEVELOPMENT COMMERCIALISATION

- Groundbreaking results precisely identify muscle damage & assess recovery in high performance athletes; interest from thoroughbred horse racing
- In professional sports muscle damage accounts for 55% of injuries – **\$1.2bn spent treating potentially avoidable injuries in Australia (2023)**



# Corporate Overview



ASX: PIQ

## Corporate Snapshot

ASX code	PIQ
Market Capitalisation	A\$55m
Cash (31 Dec 2024)	A\$5.3m
Share Price (4 April 2025)	A\$0.42
Shares on issue	131m
Revenue & other income – FY24	A\$3.6m
Average Quarterly cash burn – FY24	A\$1.6m



## Financial and Corporate

- Top 40 Shareholders hold 41%
- Directors are highly aligned with shareholders holding 13%
- Revenue generating
  - Bioanalytical service business helps offset cash burn
  - Launching four tests in 2025 for sales of PromarkerD, PromarkerEso, OxiDx & PromarkerEndo
- Corporate
  - Board renewal: Industry experienced Chair and NED appointed
  - Recruited senior executives to accelerate test commercialisation
- State-of-the-art laboratories
  - Specialist proteomics technology platform
  - Cutting edge facility with world leading accreditation: ISO 17025 (analytical) and ISO 13485 (manufacturing), expanding to include ISO 15189 (clinical testing)
  - US clinical reference laboratory established (CLIA certified)
  - Analytical services – pharmacokinetic (PK) testing & biosimilars
  - Headquartered on QEII Medical Campus, Perth, WA



## **Dr James Williams** PhD (Melbourne), MBA (UWA), BSc, Hons (Aberdeen), GAICD, Non-Executive Chair

Accomplished manager, director, scientist and investor with experience covering all aspects of life-science technology translation. Involved from startup to commercialisation, including CEO, CTO, Director and Chair roles, of numerous biotech companies (including Dimerix (DXB.ASX) and iCeutica) which have resulted in five Food and Drug Administration (FDA) approved drugs, medical devices and diagnostics.



## **Dr Richard Lipscombe** PhD (London), MA (Oxon), Co-Founder & Managing Director

Led the Company from foundation through listing in 2015 to today. Thirty years biotechnology experience in R&D and product commercialisation in commercial and academic entities. Technical expertise in chemistry, immunology, biomarker discovery & clinical proteomics.



## **Paul House** GAICD, BCommerce (UWA), Non-Executive Director

Over 25 years with multi-national corporations, CEO of Imdex (ASX:IMD), prior role as MD of SGS India for 8 years. Previously held CFO and COO roles and was Senior Manager at a leading global management consultancy firm.



## **Neville Gardiner** BBus (Accounting and Business Law) (Curtin), Non-Executive Director

Seasoned finance professional with over 30 years' experience providing corporate advice to Boards of public and private companies. He was Co-Founder and MD of Torridon Partners, an independent corporate advisory firm, which was acquired by Deloitte in 2016, where he became Partner in their M&A Advisory team.



## **Aaron Brinkworth** GAICD, BHLthSc (ECU), Non-Executive Director (appointed 8 Nov 24)

Over a 22-year career at Gilead Sciences, Inc. (Nasdaq: GILD), he held senior commercial, patient access and strategic licensing roles. Mr Brinkworth has led Gilead's Asia Pacific commercial and access operations where he was responsible for developing high performing sales, marketing, and distribution networks across the region. Mr Brinkworth currently serves as non-executive Director for Resonance Health Ltd (ASX: RHT).

# Commercialisation Team



ASX: PIQ

*Dedicated team responsible for driving commercial adoption*



**Phillip Prather**  
*Chief Commercial Officer*

Phillip brings extensive leadership in the global medical devices industry, particularly in developing new markets and successfully launching products for innovative companies including Cochlear, QIAGEN, Philips, Medtronic, and Leo Cancer Care. His experience includes regulatory, quality, and market access across major medtech markets (EU, North America, APAC). Phillip is responsible for global sales, marketing, and customer engagement activities.




**Jacqueline Gray**  
*Chief Financial Officer & Head of Corporate Development*

Jacqueline has held senior leadership roles with global media and healthcare companies, including the Economist, BBC Worldwide, and National Medical Enterprises. More recently her focus has been with high growth, emerging businesses in medical technology, Software as a Service (SaaS), digital marketing and e-commerce. Jacqueline has experience in M&A, business restructuring, and managing businesses during disruption, downturn, and exponential growth.



**Dr Pearl Tan**  
*Head of Product Development*

Pearl is responsible for the commercial delivery of the Promarker® pipeline. Since joining Proteomics International in 2014, Pearl has successfully led the manufacturing of the PromarkerD test, regulatory & PLA code submissions, and most recently the establishment of the Company's CLIA certified lab in the USA.



**Dr Johan Conradie**  
*Clinical Pathologist*


Johan is a Chemical Pathologist with over 21 years of experience in clinical biochemistry and toxicology, and gained his FRCPA in 2008 and later completed an MBA at the University of Western Australia in 2019. Johan also serves as the Medical Director of Western Diagnostic Pathology. Johan has overall responsibility for clinical results from the suite of Promarker® diagnostic tests.




# Go-to-Market optionality: Synergistic pathways

*Initial sales led by Direct to Consumer with option to expand through licencing*

## Direct to consumer (DTC) and digital marketing pathway



## Traditional licensing model





## Direct to Consumer (DTC) digital solution implemented

**PromarkerD**  
PROACTIVELY CHANGING RENAL HEALTHCARE

LOGIN(HUB) CONTACT US PRODUCT

The Test Evidence Healthcare Providers Patients Partners Investors News


### The Test

The PromarkerD test system is a blood test that assesses the risk of diabetic kidney disease in people with type 2 diabetes

REGISTER YOUR INTEREST TODAY

- Launched in Australia in Q1 CY25
  - Automated immunoassay established
  - Clinical ISO 15189 certification pending
  - Blood collection logistics established
  - GP practices engaged
  - Integrated digital solution enacted

myTEST Our Tests How it works Collection Centres About us For Doctors



### Diabetic Kidney Disease Test

Get a blood test that predicts the risk of **diabetic kidney disease (DKD)** in patients with **type 2 diabetes**.

Unlike current tests that only detect kidney disease after it develops, this advanced test identifies your risk years before symptoms appear, allowing for earlier intervention.


Request test now

- For patients with type 2 diabetes
- Predicts kidney disease 4 years early
- Sample Type: Blood Test
- Authorisation: telehealth consult included
- Results: 1 week from sample collection


Note: This test requires authorisation from a licensed medical provider. The test package includes a telehealth consultation with an independent, Australian registered doctor who can provide the necessary authorisation for your test order if you don't already have a physician to do so.

- Why do I need this test?
- Who should take this test?
- What does this test measure?
- When should I do the test?
- What to expect with your results?
- What happens after I get my result?

### How it all works


- Purchase your test**  
Request a test, and answer a few questions about your health online.
  - Talk to a clinician**  
Book a telehealth consultation with a clinician to approve your test request (included in purchase)
  - Provide your sample**  
Take your referral to a collection centre and have your blood sample taken.
  - Get answers in days**  
Access your results online through a secure portal and share them with your doctor for informed health discussions.
- 

Disclaimer: This test is conducted in line with ISO 15189:2022 standards, adhering to National Association of Testing Authorities (NATA) accredited methodologies.



# Patient journey & Revenue capture model

Managed via a fully integrated digital solution @ [www.myTEST.health](http://www.myTEST.health)



\* Electronic Medical Record (EMR) integration – GP practice software via digital (HL7 compliant) interface

^ Unique to each practice; also guides GP clinic recognition in PI-Laboratory Information Management System (LIMS)

# GP blast followed by relationship nurture workflows

## Comprehensive Customer Relationship Management (CRM) system established

**MARKET INTRODUCTION**

**A blood test which can identify the onset of chronic kidney disease up to four years before clinical symptoms appear**

Indication: Type 2 Diabetes  
Accuracy: 86% Sensitivity  
Prognostic: 4-years before clinical symptoms

**Promarker<sup>®</sup>D**


You can help your patients manage their kidney health, to slow or stop the onset of kidney disease.



Promarker<sup>®</sup>D is a proteomic biomarker-based blood test developed and distributed by Proteomics International, an Australian medical technology company at the forefront of precision diagnostics.  
www.proteomicsintl.com



Blast(s) to designated clinics (geographies, demographics, etc)  
QR to video call to action



# Market launch: Australia and USA



ASX: PIQ

	Australia	USA
<b>PI Reference Laboratory</b>	ISO 17025 established ISO 15189 pending	CLIA certification established
<b>Initial capacity of laboratory</b>	PromarkerD: 84,000 pa PromarkerEso: 32,000 pa	PromarkerD: 84,000 pa PromarkerEso: 32,000 pa
<b>Launch Date</b>	PromarkerD: Q1 CY25 PromarkerEso: Q2 CY25	PromarkerD: Q2 CY25 PromarkerEso: Q3 CY25
<b>Proteomics retained test fee</b>	>70% of test sale price	
<b>Reimbursement</b>	Self pay	Self pay & existing CMS code
<b>Pricing</b>	PromarkerD: AUD \$245 PromarkerEso: <i>tba</i> PromarkerEndo: <i>tba</i>	PromarkerD: USD \$391 PromarkerEso: <i>tba</i> PromarkerEndo: <i>tba</i>
<b>Market Size</b>	Diabetes - 1.5 million Endometriosis - 1 in 9 women GERD (Esophageal Cancer) – 2 million	Diabetes - 32 million Endometriosis - 1 in 9 women GERD (Esophageal Cancer) – 67 million

# Market launch: strategic rationale



*The Direct to Consumer route provides maximum optionality:*

- Fastest and most cost-effective path to market
- Scalable with low cost of customer acquisition compared to traditional sales model
- Provides a platform to:
  - partner with virtual care providers in this fast-growing market
  - accelerate expansion to GP practices and primary care
  - partner with advocacy groups
- Reduces risk for partners as product already in market
- Leverage more attractive terms for out-licensing
- Digital solution is readily replicated across the Promarker tests
  - accelerates expansion into US market - tech transfers & marketing content ready to go



# Multiple Value Drivers in H1 CY25



Milestone	TARGET Qtr	Q4 CY24	Q1 CY25	Q2 CY25	Impact
<b>Commercial</b>					
US reference lab established			✓		Key to first US sales and reimbursement
First Sales PromarkerD in USA					Initiate pathway to significant revenues
Australian clinical lab established			✓		
PromarkerD launched in Australia			✓		Drive global uptake and future revenue
PromarkerEndo launched in Australia					First sales
PromarkerEso launched in Australia					Launch imminent
<b>Clinical/Technical</b>					
Endometriosis Dx - results update		✓			New first-in-class diagnostic test
Esophageal Cancer Dx - results update		✓			New first-in-class diagnostic test
OxiDx test - results update		✓			New first-in-class diagnostic test
<b>Reimbursement</b>					
PromarkerD PLA code (US) application			✓		Support US roll-out

# Summary – Exceptional Growth Opportunity

- **Disruptive, cutting-edge technology & proven in-house diagnostics platform**
- **Multiple patented tests**
  - PromarkerD test de-risked, patented, commercial launch ready
  - PromarkerEso, PromarkerEndo and OxiDx tests nearing market entry
  - Tests are scalable with high margins – and address large markets
- **Team, infrastructure and certifications in place to support commercial launches**
- **First sales in the first half of this year (H1 CY25)**

## **Dr Richard Lipscombe**

### **Managing Director**

T: +61 8 9389 1992

E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

[www.proteomicsinternational.com](http://www.proteomicsinternational.com)


## **Dirk van Dissel**

### **Investor Relations**

Candour Advisory

T: +61 408 326 367

E: [dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)



# **Proteomics International**

LABORATORIES LTD

PromarkerD

*Diabetic Kidney Disease*

COMMERCIALISATION

PromarkerEndo

*Endometriosis*

DEVELOPMENT COMMERCIALISATION

PromarkerEso

*Esophageal Cancer*

DEVELOPMENT COMMERCIALISATION

OxiDx

*Oxidative Stress*

DEVELOPMENT COMMERCIALISATION


Supplemental – the Promarker<sup>®</sup> suite of diagnostic tests

# The Need: Target Populations for DKD, Endo and Eso

Targeting initially the US and Australian markets, with EU and other jurisdictions to follow

## Promarker<sub>D</sub>


10.5% of the global adult population have diabetes



Target market = 33.5 million adults

## Promarker<sub>Endo</sub>


1 in 9 women have endometriosis



Target market = 71 million women

## Promarker<sub>Eso</sub>

10-20% western populations have Gastroesophageal reflux disease (GERD)



Target market = 69 million people



# PromarkerD: Diabetic Kidney Disease



## Intellectual Property



Patents granted in all major jurisdictions - PromarkerD Patent family & Trademark covers **72%** of the world's diabetes patients

## Regulatory



**CE Mark** (EU) registration received for the PromarkerD Immunoassay IVD  
US sales utilising Lab Developed Test (LDT) pathway via CLIA certified laboratories; Australia utilising ISO 15189 pathway



## Manufacturing scale-up



ISO 13485 certified EU manufacturer  
Simple technology platform (immunoassay) – easy to use and integrate into existing pathology lab processes

## Peer Reviewed



PromarkerD tested on over **5,000 patients** in 4-year clinical studies  
Global multi-centre clinical study (CANVAS) on 3,568 participants in collaboration with Janssen (J&J)  
Clinical & analytical validity proven (Sensitivity 86%); 10+ Peer Reviewed Publications



## Physician Support




**Clinical utility demonstrated** - US based survey showed **96%** of physicians were likely to use PromarkerD test scores for clinical decision making; PromarkerD consistently ranked as one of the top 2 factors driving physician decision-making.

## Outperforms Standard of Care



857 community-based patients tested for existing DKD at baseline: 497 had normal kidney function  
PromarkerD accurately predicted 84% (N=38); All were missed by Standard of Care tests



## The Need



**Economic Cost:** Chronic Kidney Disease cost Australia A\$9.9bn in 2021 (Kidney Health Australia) - investment in early detection could yield a net benefit of \$10.2bn over 20 years; Kidney Research UK have declared a public health emergency - by 2033 kidney disease risks costing the UK economy £13.9bn annually

## The Treatments



**New renal protective therapies:** SGLT2-inhibitors approved & potential use of GLP-1 agonist semaglutide (Ozempic)  
PromarkerD identifies patients for better management of diabetes, adherence to medications, and focus on diet & exercise

## The Utility



**Complementary diagnostic** - Early diagnosis of DKD using PromarkerD can help inform doctors' treatment decisions to improve clinical outcomes for patients. Actions taken BEFORE the onset of DKD

## Breakthrough Study



**PromarkerD validated for Type 1 (T1D) diabetes** - demonstrated **high accuracy** (AUC of 0.93) in predicting chronic kidney disease in patients with T1D (represents 10% of all diabetes cases); Offers a new target market

# My impression on Promarker<sup>®</sup>D market release

*What are our Key Opinion Leaders saying?*



**Professor Merlin Thomas**, MBChB, PhD, FRACP, FAAHMS  
Nephrologist  
Department of Diabetes, Monash University, Australia

*"When kidney function is lost, it is lost forever. Identifying people at increased risk of developing impaired kidney function before this function is irreversibly gone is the best way to protect their kidneys and their health."*

*The saddest thing you hear as a nephrologist is the regret, "I wish I had known earlier!"*

*"There has been a sea-change in relation to the management of cardiorenal metabolic disorders with the recognition of the need to take a more preventative approach rather than waiting until cardiorenal damage has occurred.*

*Waiting for the appearance of albuminuria and cardiovascular disease should no longer be our number one priority and PromarkerD may offer people with diabetes an opportunity to manage risk before damage has occurred."*



**Dr Andrew Frankel**, MBBS, BSc, MD, FRCP  
Consultant Physician and Nephrologist  
Imperial College Healthcare NHS Trust, UK

# PromarkerEso: Esophageal Cancer

## First-in-class blood test 'PromarkerEso' ready for commercialisation

**Clinical question – can a blood test distinguish between individuals who are:**

- 1) **healthy**
- 2) **esophageal adenocarcinoma (EAC) patients**
  - Only 50% of EAC patients report chronic acid reflux (GERD)
  - 90% of EAC cases continue to remain undetected
  - 25% of EAC cases misdiagnosed as negative by endoscopy

### Test status

- **Test shows 94% accuracy** in diagnosing patients with and without the disease  
(World Congress Esophageal Diseases, 2024)
- Advanced statistical modelling being refined using 'traffic light' system to **improve test performance for clinical use**
- New clinical results **submitted for peer review publication**
- Methodology (mass spectrometry) being **adapted for clinical launch**
- **Patents granted in Europe, China, Australia**; USA pending
- Discussions underway to establish test in reference laboratories worldwide
- Proteomics International preparing to **launch PromarkerEso in Australia** under ISO 15189 accreditation, now targeting **Q2 CY25**

***A non-invasive blood test for esophageal cancer could transform the way this disease is detected and is attracting interest from world leaders in EAC treatment***

### Clinical studies

- **Development and Validation** - Collaboration with QIMR Berghofer Medical Research Institute analysed 302 samples across two patient cohorts: (World Congress Esophageal Diseases, 2023)
  - ❑ PROBE-NET study, Australia (N=249)
  - ❑ Ochsner Health System, USA (N=49)
- **Clinical validation** - biomarker panel confirmed in independent patient cohort from Victoria Cancer Biobank (N=165)  
(Lorne Proteomics Symposium, Feb '24)
- **Clinical validation** – analysis of samples from Victoria Cancer Biobank confirmed clinical performance of the test (N=165)  
(World Congress Esophageal Diseases, 2024)

# My impression on Promarker<sup>®</sup>Eso market release



*What are our Key Opinion Leaders saying?*



**Professor Robert Odze, MD, FRCPc**  
Senior Consultant Pathologist, Professor of Pathology  
Tufts University Medical School, USA

*"As a pathologist, I am keenly aware of the multitude of problems and limitations we have regarding detection of esophageal cancer and its precursors based on tissue analysis.*

*Proteomic biomarker serum analysis represents a new approach that would greatly reduce the current problems we face in cancer detection and enable better early and more accurate risk prediction.*

*Incorporating serum-based biomarkers that can be used in the general population will enhance our ability to detect cancer and save lives, both of which are in great need for patients at risk for esophageal cancer"*


*"The early, prompt detection and precise risk assessment of esophageal adenocarcinoma will enable curative treatment for this disease. Advanced diagnostics, in particular PromarkerEso, are proving to be an important and effective way to transform the outcomes for our patients"*



**Professor Hugh Barr, MD (Dist), ChM, FRCS, FRCSE, FHEA, FOD**  
Consultant General & Gastrointestinal Surgeon  
Gloucestershire Hospitals NHS Foundation Trust, UK



# PromarkerEndo: Endometriosis



ASX: PIQ

## First-in-class blood test 'PromarkerEndo' nearing commercialisation

Clinical question – can a blood test distinguish between individuals who are:

- 1) healthy
- 2) symptomatic patients (pelvic pain but surgically-diagnosed absence of endometriosis)
- 3) endometriosis patients (confirmed by laparoscopy – 4 stages: minimal/mild/moderate/severe)

### Test status

- **Excellent diagnostic performance published for prototype PromarkerEndo test in identifying all stages of endometriosis with high accuracy** (*Human Reproduction 2024*)
  - endo vs healthy controls: Sensitivity 96%, Specificity 98%
  - stage IV endo vs symptomatic controls: Sensitivity 98%, Specificity 96%
  - stage I endo vs symptomatic controls: Sensitivity 87%, Specificity 72%
- Advanced statistical modelling being finalised using 'traffic light' system to **improve test performance for clinical use**
- Methodology (mass spectrometry) being **adapted for clinical launch**
- **Patents pending** in all major jurisdictions
- Discussions underway to establish test in reference laboratories worldwide
- Proteomics International preparing to **launch PromarkerEndo in Australia** under ISO 15189 accreditation, now targeting **Q2/Q3 CY25**

***A non-invasive blood test for endometriosis is a potential 'game-changer' in women's health and the published results have attracted interest worldwide***

### Clinical studies

- *Development* - biomarker panel (Wesley Medical Research Biobank N=56 samples)
- *Validation* - Collaboration with Royal Women's Hospital & University of Melbourne analysed (endometriosis N=464; healthy individuals N=153; symptomatic controls N=132) (*World Endometriosis Conference, May '23*)
- *Confirmation results* - Peer reviewed and published (*Journal Human Reproduction, Dec 24*)
- *Further studies* - Collaboration ongoing with University of Oxford for international validation study (N=600 samples)



## Groundbreaking blood test nearing commercialisation

### What is Oxidative Stress?

- Oxidative stress occurs when the body's antioxidant defences are overwhelmed by an excess of toxic oxidants
- **Oxidative stress is implicated in over 70 health conditions** with levels often reflective of a person's health condition

### OxiDx – blood test to monitor oxidative stress

- OxiDx P/L was spun out of PIQ and the University of Western Australia in Aug 2022

### World first test:

- **Accurate** - highly sensitive
- **Simple to use** – finger prick sample
- **Cost effective** – for mass market use
- **Peer reviewed** – multiple journal publications
- **Patented** – patent families cover Australia & USA, Europe & Japan; others pending





### Targeting commercial use of OxiDx technology:

- **Athletic monitoring tool for competition preparedness:**
  - **Professional Sports** – performance, recovery and injury risk management – 55% of sports injuries are muscle related
    - World first results published showing **OxiDx test can identify muscle damage and assess recovery in elite athletes** (*Physiological Reports, Dec 2024*)
  - **Thoroughbred Racing Industry** – injury risk management and race-preparedness - 85% of Thoroughbreds suffer injury in their first 2-3 yrs
    - [Proof-of-concept study being finalised](#)

### New commercialisation pathways:

- Potential spin-out or partnering opportunity across sports & horse racing industries
- Proteomics International preparing to **launch OxiDx in Australia** under ISO 17025 accreditation, targeting **Q3 CY25**



## Identity

Proteomics International is a medical technology company specialising in predictive diagnostics and advanced analytical services using proteomics – the industrial scale study of the structure and function of proteins.

## Mission

To improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

## Vision

To help create a world where disease is detected early and cured simply.